Overview of PCSK9 Inhibitors
Dates and Times
Start: 10/25/2017 7:45 AM
End: 10/25/2017 8:45 AM
- Discuss landscape of CVD risk reduction guidelines including LDL targets and drug recommendations
- Review options for lifestyle, supplemental, and pharmacological management of dyslipidemia
- Clarify the mechanism of action of PCSK9 inhibitors and the knowledge on effectiveness and efficacy
- Discuss the obstacles to use of PCSK9i, including patient qualifications, insurance denials, and financial burden
Lecture Hall 2
Level 2 HSC
100 Nicolls Road
Stony Brook, NY 11794
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.